Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019

Q4 FY24 results · Jan–Mar 2024

Jubilant Pharmova reported revenue from operations of ₹175.86 crore (down 89.5% from Q4 FY23) and net loss of ₹6.18 crore for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY24	Q4 FY23	YoY	Q3 FY24	QoQ
Revenue from operations	175.86	1,678.00	−89.5%	1,677.10	−89.5%
Other income	1.44	4.45	−67.6%	35.80	−96.0%
Total income	177.30	1,682.45	−89.5%	1,712.90	−89.6%
Profit before share of associates & JVs and tax	(5.71)	(103.12)	Loss narrowed	87.90	Turned loss
Share of profit/(loss) of associates & JVs	0.34	16.71		13.10
Net profit for the period	(6.18)	(100.51)	Loss narrowed	66.40	Turned loss
Attributable to shareholders of the company	(5.86)	(97.84)	Loss narrowed	66.80	Turned loss
EPS, basic (₹)	(3.69)	(6.15)	not comparable	4.22	not comparable
Net margin (%)	-3.5	-6.0		4.0

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY24	Q4 FY23	YoY	Q3 FY24	QoQ
Revenue from operations	205.80	199.84	+3.0%	175.20	+17.5%
Other income	50.10	13.66	+266.8%	19.00	+163.7%
Total income	255.90	213.50	+19.9%	194.20	+31.8%
Profit before tax	41.50	(1.23)	Turned profit	(2.30)	Turned profit
Net profit for the period	32.50	(30.86)	Turned profit	(2.40)	Turned profit
EPS, basic (₹)	2.05	(1.94)	Turned profit	(0.15)	Turned profit
Net margin (%)	15.8	-15.4		-1.4

Consolidated

Filed with BSE: 01 Jun 2024, 14:38 IST
Board meeting: 29 May 2024
Period: 01 Jan 2024 to 31 Mar 2024
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 01 Jun 2024, 14:38 IST
Board meeting: 29 May 2024
Period: 01 Jan 2024 to 31 Mar 2024
Review status: Audited
Source: XBRL filing on BSE